E. Heath

951 total citations
15 papers, 606 citations indexed

About

E. Heath is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Surgery. According to data from OpenAlex, E. Heath has authored 15 papers receiving a total of 606 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 5 papers in Molecular Biology and 4 papers in Surgery. Recurrent topics in E. Heath's work include Prostate Cancer Treatment and Research (4 papers), Esophageal Cancer Research and Treatment (4 papers) and Epigenetics and DNA Methylation (3 papers). E. Heath is often cited by papers focused on Prostate Cancer Treatment and Research (4 papers), Esophageal Cancer Research and Treatment (4 papers) and Epigenetics and DNA Methylation (3 papers). E. Heath collaborates with scholars based in United States, Japan and Denmark. E. Heath's co-authors include Craig M. Hooker, Edward Gabrielson, Stephen B. Baylin, Mingzhou Guo, Michael G. House, Yu Han, Stephen C. Yang, Malcolm V. Brock, James G. Herman and Asmita Vaishnav and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and The FASEB Journal.

In The Last Decade

E. Heath

14 papers receiving 597 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Heath United States 8 395 149 144 102 72 15 606
Noritaka Yabuki Japan 11 319 0.8× 135 0.9× 108 0.8× 195 1.9× 109 1.5× 12 596
Christine Heinzle Austria 15 378 1.0× 107 0.7× 52 0.4× 75 0.7× 77 1.1× 37 606
Wenjie Zhang China 17 407 1.0× 193 1.3× 115 0.8× 58 0.6× 120 1.7× 47 649
Jera Jeruc Slovenia 13 222 0.6× 103 0.7× 88 0.6× 88 0.9× 45 0.6× 31 466
Hang Lv China 15 249 0.6× 152 1.0× 132 0.9× 84 0.8× 126 1.8× 34 505
Jesús Méndez‐González Spain 9 361 0.9× 194 1.3× 117 0.8× 117 1.1× 94 1.3× 11 601
Yueqing Tang China 10 205 0.5× 118 0.8× 96 0.7× 94 0.9× 94 1.3× 20 447
Cheng Su China 16 376 1.0× 127 0.9× 122 0.8× 80 0.8× 116 1.6× 50 725

Countries citing papers authored by E. Heath

Since Specialization
Citations

This map shows the geographic impact of E. Heath's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Heath with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Heath more than expected).

Fields of papers citing papers by E. Heath

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Heath. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Heath. The network helps show where E. Heath may publish in the future.

Co-authorship network of co-authors of E. Heath

This figure shows the co-authorship network connecting the top 25 collaborators of E. Heath. A scholar is included among the top collaborators of E. Heath based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Heath. E. Heath is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Zarka, Jonathan, Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, et al.. (2025). 2403P LuRa: Efficacy and Tolerability of Radium-223 Following [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer. Annals of Oncology. 36. S1223–S1223.
2.
Linch, Mark, Simon J. Crabb, E. Heath, et al.. (2022). 1397P Phase I results of exicorilant plus enzalutamide in patients with castration-resistant prostate cancer. Annals of Oncology. 33. S1183–S1183. 2 indexed citations
3.
Kalpage, Hasini A., Maurice‐Andre Recanati, Alemu Fite, et al.. (2018). Tissue‐specific regulation of cytochrome c by post‐translational modifications: respiration, the mitochondrial membrane potential, ROS, and apoptosis. The FASEB Journal. 33(2). 1540–1553. 180 indexed citations
4.
Taplin, Mary Ellen, K.N. Chi, Franklin Chu, et al.. (2014). Galeterone in 4 Patient Populations of Men with Crpc: Results from Armor2. Annals of Oncology. 25. iv257–iv257. 5 indexed citations
5.
Kong, Dong, E. Heath, Wei Chen, et al.. (2012). Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment.. PubMed. 4(1). 102–103. 70 indexed citations
6.
Holen, Kyle D., E. Heath, William R. Schelman, et al.. (2010). Phase I first-in-human study of the centromere-associated protein E (CENP-E) inhibitor GSK923295 in patients with advanced solid tumors (study CPE107602).. Journal of Clinical Oncology. 28(15_suppl). 3012–3012. 2 indexed citations
7.
Shapiro, Geoffrey I., E. Heath, Lisa Malburg, et al.. (2007). A Phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics of XL880, a VEGFR and MET kinase inhibitor, administered daily to patients (pts) with advanced malignancies. Molecular Cancer Therapeutics. 6. 8 indexed citations
8.
Heath, E., et al.. (2007). Lycopene: prospects for chemoprevention and treatmentof prostate cancer.. CABI Reviews. 1 indexed citations
9.
Ying, Hao, et al.. (2005). A novel computerized approach to enhancing lung tumor detection in whole-body PET images. PubMed. 3. 1589–1592. 10 indexed citations
10.
Gibson, Michael K., et al.. (2004). Effect of neoadjuvant chemoradiotherapy on pathologic stage and survival in patients with locally advanced esophageal cancer. Journal of Clinical Oncology. 22(14_suppl). 4032–4032. 1 indexed citations
11.
Gibson, Michael K., et al.. (2004). Effect of neoadjuvant chemoradiotherapy on pathologic stage and survival in patients with locally advanced esophageal cancer. Journal of Clinical Oncology. 22(14_suppl). 4032–4032. 2 indexed citations
12.
Guo, Mingzhou, Yoshimitsu Akiyama, Michael G. House, et al.. (2004). Hypermethylation of the GATA Genes in Lung Cancer. Clinical Cancer Research. 10(23). 7917–7924. 107 indexed citations
13.
Guo, Mingzhou, Michael G. House, Craig M. Hooker, et al.. (2004). Promoter Hypermethylation of Resected Bronchial Margins. Clinical Cancer Research. 10(15). 5131–5136. 138 indexed citations
14.
Heath, E., Marcia Irene Canto, Steven Piantadosi, et al.. (2003). Chemoprevention for Barrett’s Esophagus Trial. Design and outcome measures. Diseases of the Esophagus. 16(3). 177–186. 29 indexed citations
15.
Kleinberg, Lawrence, Jonathan Knisely, Richard F. Heitmiller, et al.. (2003). Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. International Journal of Radiation Oncology*Biology*Physics. 56(2). 328–334. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Noritaka Yabuki Breakdown of academic impact, for papers by Christine Heinzle Breakdown of academic impact, for papers by Wenjie Zhang Breakdown of academic impact, for papers by Jera Jeruc Breakdown of academic impact, for papers by Hang Lv Breakdown of academic impact, for papers by Jesús Méndez‐González Breakdown of academic impact, for papers by Yueqing Tang Breakdown of academic impact, for papers by Cheng Su
Rankless by CCL
2026